New hope for aggressive lung cancer: drug duo aims to extend remission

NCT ID NCT07110103

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Mar 08, 2026 · Last updated May 30, 2026 · Updated 13 times

Summary

This study tests whether combining golidocitinib with a PD-1 inhibitor can help keep extensive-stage small cell lung cancer from progressing after initial treatment. About 20 adults with untreated advanced SCLC will receive the drug combo as maintenance therapy. Researchers will track how long patients live without the cancer worsening and monitor side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Xinqiao Hospital, Third Military Medical University
RECRUITING

Chongqing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SCLC SCLC, EXTENSIVE STAGE